Pharmacokinetics of adalimumab in Crohn's disease

European Journal of Clinical Pharmacology

Volumn 71, Issue 9, 2015, Pages 1155-1157

  Ternant, David ^a,b   Karmiris, Konstantinos ^c   Vermeire, Severine ^c   Desvignes, Céline ^a,b   Azzopardi, Nicolas ^a   Bejan Angoulvant, Theodora ^a,b   Van Assche, Gert ^c   Paintaud, Gilles ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Adalimumab; Crohn's disease; Monoclonal antibody; Pharmacokinetics; Population compartmental modeling

Indexed keywords

ADALIMUMAB; ADALIMUMAB ANTIBODY; ANTIBODY; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ABSORPTION RATE CONSTANT; ADULT; ANTIBODY DETECTION; ARTICLE; COMPARTMENT MODEL; CONCENTRATION (PARAMETERS); CROHN DISEASE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; ELIMINATION HALF-LIFE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; BIOLOGICAL MODEL; BLOOD; METABOLISM;

ADALIMUMAB; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL;

EID: 84938992270     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-015-1892-1     Document Type: Article

References (12)

1. Ternant D, Ducourau E, Fuzibet P, Vignault C, Watier H, Lequerre T, Xavier LL, Vittecoq O, Goupille P, Mulleman D, Paintaud G (2014) Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol 2014(16):12509
2. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK (2003) Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 25(6):1700-1721
3. Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P (2009) Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 137(5):1628-1640
4. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305(14):1460-1468. doi: 10.1001/jama.2011.406
5. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66(7):921-926
6. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K (2009) Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 68(11):1739-1745. doi: 10.1136/ard.2008.092833
7. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ (2008) Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 28(9):1122-1126
8. Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, Davis HM, Zhou H (2009) Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 65(12):1211-1228. doi: 10.1007/s00228-009-0718-4
9. Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, Paintaud G (2008) Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 30(4):523-529
10. Ternant D, Mulleman D, Lauferon F, Vignault C, Ducourau E, Wendling D, Goupille P, Paintaud G (2012) Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. Br J Clin Pharmacol 73(1):55-65
11. Xu Z, Seitz K, Fasanmade A, Ford J, Williamson P, Xu W, Davis HM, Zhou H (2008) Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 48(6):681-695
12. Ternant D, Mulleman D, Degenne D, Willot S, Guillaumin JM, Watier H, Goupille P, Paintaud G (2006) An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit 28(2):169-174